This announcement is a separate document:
Amplia Therapeutics Ltd: Amplia Reports First Patient Dosing In Phase 2a Accent Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.